Oncogenes and Molecular Genetics of Urological Tumours

Understanding DNA changes in urological cancers; oncogenes and molecular genetics of renal tumours; oncogenes and molecular genetics of bladder cancer; genetic steps associated with prostate cancer development; cytogenetics and molecular biology of testicular germ cell tumours; specific detection of metastasized human tumour cells in embryonic chicks by the polymerase chain reaction; cytogenetic abnormalities in renal cell carcinoma; genes involved in oncogenesis and drug-resistance in kidney cancer; abnormal expression of proteasomes (multicatalytic proteinase complexes) in human renal cancers; bladder cancer survival and human papillomavirus infection - immunohistory and in-situ hybridization; the role of ras p21 oncoprotein in human bladder cancer; study of ras gene alterations in human bladder tumours; amplification and expression of the c-erb B-2; neu and c-myc proto-oncogenes in bladder cancer and renal cell carcinoma; induction of transforming growth factor alpha and oncogenes in bladder cancer; immunohistochemical expression of epidermal growth factor receptor and proto-oncogene erbB2 in transitional cell carcinoma of the bladder; expression of multi-drug resistance gene product (P-glycoprotein) in normal urothelium and urothelial tumours; prostate cell proliferation and programmed death share in early molecular pathway regulated by androgens; correlation between restriction fragment length polymorphism of the L-myc gene and lymph node metastasis in prostate cancer; alterations of the p53 gene involved in the progression of a human prostate carcinoma; progression of androgen-dependent tumour to androgen-independent tumour; allelotype of urothelial and prostatic cancers; the oncogenic human papillomavirus types 16 and 18 not involved in human prostate carcinogenesis.